Home > Financial Ratios > LINCOLN PHARMACEUTICALS

LINCOLN PHARMACEUTICALS
Core EBITDA Growth

    Back to All Ratios
LINCOLN PHARMACEUTICALS is part of below Screeners ↓
Top Small Cap Stocks with Best Fundamentals
Best Quarterly Growth Small Cap Stocks
Best 1M Momentum Small Cap Stocks
AD     Remove this Ad

LINCOLN PHARMACEUTICALS Last 5 Year Core EBITDA Growth History

[Consolidated]

Mar2025Mar2024Mar2023Mar2022Mar2021
   Core EBITDA Growth(%) -7.7120.295.8813.6121.24

What is the latest Core EBITDA Growth ratio of LINCOLN PHARMACEUTICALS ?

The latest Core EBITDA Growth ratio of LINCOLN PHARMACEUTICALS is -7.71 based on Mar2025 Consolidated results.
Year Core EBITDA Growth
Mar2025-7.71
Mar202420.29
Mar20235.88
Mar202213.61
Mar202121.24

How is Core EBITDA Growth of LINCOLN PHARMACEUTICALS Trending?

Years Core EBITDA Growth % Change
Mar2025 -7.71
Negative
Mar2024 20.29
245.07
Mar2023 5.88
-56.80
Mar2022 13.61
-35.92
Mar2021 21.24 -

Other Financial Ratios of LINCOLN PHARMACEUTICALS


Compare Core EBITDA Growth ratio of peers of LINCOLN PHARMACEUTICALS

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
LINCOLN PHARMACEUTICALS ₹1,233.2 Cr -2.9% 37% 9.5% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹415,217.0 Cr 0.4% 5.6% 1.8% Stock Analytics
DIVIS LABORATORIES ₹166,047.0 Cr -0.5% 3.3% 7.9% Stock Analytics
TORRENT PHARMACEUTICALS ₹148,872.0 Cr 4.5% 10% 41.5% Stock Analytics
DR REDDYS LABORATORIES ₹108,454.0 Cr 1.5% 4.8% 9.1% Stock Analytics
CIPLA ₹107,136.0 Cr -1.7% 1% -10.5% Stock Analytics


LINCOLN PHARMACEUTICALS Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
LINCOLN PHARMACEUTICALS

-2.9%

37%

9.5%

SENSEX

-1.5%

0.8%

8.2%


You may also like the below Video Courses